Company Overview
About Nusano
Nusano is a radioisotope production technology company founded in 2017 and headquartered in Seattle, Washington. The company has developed a proprietary high-current linear accelerator (linac) technology designed to produce diagnostic and therapeutic radioisotopes outside of the nuclear reactor supply chain. Conventional medical radioisotope production relies heavily on aging nuclear research reactors and uranium-based processes — creating chronic supply chain vulnerabilities that periodically cause shortages of critical isotopes like Tc-99m (used in millions of cardiac and oncology scans annually). Nusano's linac technology produces isotopes without uranium, offering pharmaceutical manufacturers and hospitals a more stable, reactor-independent supply alternative.
Business Model & Competitive Advantage
The company raised $22M in a funding round in 2022 to advance development of its accelerator platform and scale production capacity for pharmaceutical-grade radioisotopes. Nusano's commercial focus is on supplying isotopes to radiopharmaceutical companies developing targeted cancer therapies and precision diagnostic agents — a market experiencing rapid growth driven by FDA approvals of drugs like Lutathera and Pluvicto (Novartis) and the entrance of major pharma players including Eli Lilly, Bristol-Myers Squibb, and AstraZeneca into radiopharmaceutical oncology.
Competitive Landscape 2025–2026
Nusano operates at the supply chain infrastructure layer of the radiopharmaceutical industry rather than as a drug developer itself — positioning as an isotope manufacturer and production technology provider. Its uranium-free approach also carries regulatory and geopolitical advantages: as global nuclear non-proliferation concerns intensify, alternatives to highly enriched uranium (HEU)-dependent isotope production are attracting increasing policy support and strategic investment from healthcare systems seeking supply resilience.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare Nusano with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Nusano? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Nusano Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Nusano vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →